Retour à la liste des essais cliniquesLung cancer

CodeBreak202

A Phase 3, Multicenter, Randomized, Open-label;Study Evaluating Efficacy of Sotorasib Platinum;Doublet Combination Versus Pembrolizumab;Platinum Doublet Combination as a Front-Line;Therapy in Subjects With Stage IV or Advanced;Stage IIIB/C Nonsquamous NonÀSmall Cell Lung;Cancers, Negative for PD-L1, and Positive for;KRAS p.G12C (CodeBreaK 202)

Ouvert à Paris depuis le : 18/03/2024
Public cible : Adult
Phase : Phase III

Description de l'essai

To compare progression-free survival;(PFS) in subjects who receive;sotorasib with platinum doublet;chemotherapy versus subjects who;receive pembrolizumab with platinum;doublet chemotherapy.

Url of the trial

Investigateur principal

NICOLAS GIRARD

Professeur - Médecin

Contacter